This company has been acquired
Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!
Freeline Therapeutics Holdings Gelecekteki Büyüme
Future kriter kontrolleri 5/6
Freeline Therapeutics Holdings is forecast to grow earnings and revenue by 60.7% and 52.7% per annum respectively while EPS is expected to grow by 75.9% per annum.
Anahtar bilgiler
60.7%
Kazanç büyüme oranı
75.9%
EPS büyüme oranı
| Biotechs kazanç büyümesi | 28.8% |
| Gelir büyüme oranı | 52.7% |
| Gelecekteki özkaynak getirisi | n/a |
| Analist kapsamı | Low |
| Son güncelleme | 15 Dec 2023 |
Gelecekteki son büyüme güncellemeleri
Recent updates
Calculating The Intrinsic Value Of Freeline Therapeutics Holdings plc (NASDAQ:FRLN)
Jul 13
Here's Why Freeline Therapeutics Holdings (NASDAQ:FRLN) Must Use Its Cash Wisely
Apr 11Here's Why Freeline Therapeutics Holdings (NASDAQ:FRLN) Must Use Its Cash Wisely
Dec 20We're Keeping An Eye On Freeline Therapeutics Holdings' (NASDAQ:FRLN) Cash Burn Rate
Aug 30Freeline gains as NEJM publishes long-term data for hemophilia therapy
Jul 21Is Freeline Therapeutics Holdings (NASDAQ:FRLN) In A Good Position To Invest In Growth?
May 05Will Freeline Therapeutics Holdings (NASDAQ:FRLN) Spend Its Cash Wisely?
Jan 13Companies Like Freeline Therapeutics Holdings (NASDAQ:FRLN) Could Be Quite Risky
Sep 30Here's Why We're Watching Freeline Therapeutics Holdings' (NASDAQ:FRLN) Cash Burn Situation
Jun 03What Kind Of Shareholders Hold The Majority In Freeline Therapeutics Holdings plc's (NASDAQ:FRLN) Shares?
Feb 18
Kazanç ve Gelir Büyüme Tahminleri
| Tarih | Gelir | Kazançlar | Serbest Nakit Akışı | Faaliyetlerden Nakit | Avg. Analist Sayısı |
|---|---|---|---|---|---|
| 12/31/2026 | 62 | 16 | 3 | 3 | 1 |
| 12/31/2025 | 21 | 12 | 0 | 0 | 2 |
| 12/31/2024 | N/A | -21 | -23 | -23 | 2 |
| 12/31/2023 | 0 | -76 | -66 | -65 | 2 |
| 9/30/2023 | 1 | -50 | -69 | -64 | N/A |
| 6/30/2023 | 1 | -53 | -77 | -71 | N/A |
| 3/31/2023 | N/A | -61 | -77 | -70 | N/A |
| 12/31/2022 | N/A | -89 | -85 | -78 | N/A |
| 9/30/2022 | N/A | -101 | -79 | -76 | N/A |
| 6/30/2022 | N/A | -117 | -86 | -83 | N/A |
| 3/31/2022 | N/A | -132 | -102 | -100 | N/A |
| 12/31/2021 | N/A | -140 | -112 | -108 | N/A |
| 9/30/2021 | N/A | -144 | -129 | -124 | N/A |
| 6/30/2021 | N/A | -138 | -136 | -132 | N/A |
| 3/31/2021 | N/A | -115 | -115 | -111 | N/A |
| 12/31/2020 | N/A | -96 | -97 | -95 | N/A |
| 9/30/2020 | N/A | -73 | -73 | -72 | N/A |
| 6/30/2020 | N/A | -63 | -53 | -51 | N/A |
| 3/31/2020 | N/A | -58 | -57 | -54 | N/A |
| 12/31/2019 | N/A | -54 | -55 | -52 | N/A |
| 12/31/2018 | N/A | -33 | -30 | -26 | N/A |
| 9/30/2017 | N/A | -17 | -20 | -19 | N/A |
Analist Gelecek Büyüme Tahminleri
Kazançlar ve Tasarruf Oranları: FRLN is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.3%).
Kazançlar ve Piyasa: FRLN is forecast to become profitable over the next 3 years, which is considered above average market growth.
Yüksek Büyüme Kazançları: FRLN is expected to become profitable in the next 3 years.
Gelir ve Pazar: FRLN's revenue (52.7% per year) is forecast to grow faster than the US market (8.2% per year).
Yüksek Büyüme Geliri: FRLN's revenue (52.7% per year) is forecast to grow faster than 20% per year.
Hisse Başına Kazanç Büyüme Tahminleri
Gelecekteki Özkaynak Getirisi
Gelecekteki ROE: Insufficient data to determine if FRLN's Return on Equity is forecast to be high in 3 years time